Krzysztof Nieznanski

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7391430/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Amyloidogenesis of Tau protein. Protein Science, 2017, 26, 2126-2150.	3.1	102
2	Phosphorus Dendrimers Affect Alzheimer's (Aβ _{1–28}) Peptide and MAP-Tau Protein Aggregation. Molecular Pharmaceutics, 2012, 9, 458-469.	2.3	98
3	Soluble Prion Protein Inhibits Amyloid-β (Aβ) Fibrillization and Toxicity. Journal of Biological Chemistry, 2012, 287, 33104-33108.	1.6	79
4	Direct interaction between prion protein and tubulin. Biochemical and Biophysical Research Communications, 2005, 334, 403-411.	1.0	64
5	Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease. Neurobiology of Disease, 2016, 91, 124-131.	2.1	40
6	Tubulin binding protein, CacyBP/SIP, induces actin polymerization and may link actin and tubulin cytoskeletons. Biochimica Et Biophysica Acta - Molecular Cell Research, 2010, 1803, 1308-1317.	1.9	38
7	CacyBP/SIP interacts with tubulin in neuroblastoma NB2a cells and induces formation of globular tubulin assemblies. Biochimica Et Biophysica Acta - Molecular Cell Research, 2007, 1773, 1628-1636.	1.9	37
8	Prion protein inhibits microtubule assembly by inducing tubulin oligomerization. Biochemical and Biophysical Research Communications, 2006, 349, 391-399.	1.0	34
9	Amyloidogenic cross-seeding of Tau protein: Transient emergence of structural variants of fibrils. PLoS ONE, 2018, 13, e0201182.	1.1	30
10	Telokin (kinase-related protein) modulates the oligomeric state of smooth-muscle myosin light-chain kinase and its interaction with myosin filaments. Biochemical Journal, 1997, 322, 65-71.	1.7	29
11	Interaction between Prion Protein and Aβ Amyloid Fibrils Revisited. ACS Chemical Neuroscience, 2014, 5, 340-345.	1.7	28
12	Characterization of Caulobacter crescentus FtsZ Protein Using Dynamic Light Scattering. Journal of Biological Chemistry, 2012, 287, 23878-23886.	1.6	26
13	Prion protein region 23–32 interacts with tubulin and inhibits microtubule assembly. Proteins: Structure, Function and Bioinformatics, 2009, 77, 279-296.	1.5	25
14	Interactions of Prion Protein With Intracellular Proteins: So Many Partners and no Consequences?. Cellular and Molecular Neurobiology, 2010, 30, 653-666.	1.7	25
15	The monomers, oligomers, and fibrils of amyloid-β inhibit the activity of mitoBKCa channels by a membrane-mediated mechanism. Biochimica Et Biophysica Acta - Biomembranes, 2020, 1862, 183337.	1.4	22
16	Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1995, 1260, 35-42.	2.4	20
17	Curcumin disrupts meiotic and mitotic divisions via spindle impairment and inhibition of CDK1 activity. Cell Proliferation, 2010, 43, 354-364.	2.4	19
18	Kinase-related protein (telokin) is phosphorylated by smooth-muscle myosin light-chain kinase and modulates the kinase activity. Biochemical Journal, 1997, 328, 425-430.	1.7	15

Krzysztof Nieznanski

#	Article	IF	CITATIONS
19	Tau inhibits tubulin oligomerization induced by prion protein. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 1845-1853.	1.9	15
20	Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 2143-2153.	1.8	14
21	Ca2+ binding to myosin regulatory light chain affects the conformation of the N-terminus of essential light chain and its binding to actin. Archives of Biochemistry and Biophysics, 2003, 417, 153-158.	1.4	11
22	Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism. Carcinogenesis, 1996, 17, 383-387.	1.3	10
23	The effects of the interaction of myosin essential light chain isoforms with actin in skeletal muscles Acta Biochimica Polonica, 2002, 49, 709-719.	0.3	10
24	Order-disorder structural transitions in synthetic filaments of fast and slow skeletal muscle myosins under relaxing and activating conditions Acta Biochimica Polonica, 2000, 47, 1007-1017.	0.3	9
25	Proteolytic processing and glycosylation influence formation of porcine prion protein complexes. Biochemical Journal, 2005, 387, 93-100.	1.7	8
26	Prion protein impairs kinesin-driven transport. Biochemical and Biophysical Research Communications, 2012, 425, 788-793.	1.0	8
27	Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein. Biochimica Et Biophysica Acta - Molecular Cell Research, 2015, 1853, 2228-2239.	1.9	8
28	Neurotoxicity of oligomers of phosphorylated Tau protein carrying tauopathy-associated mutation is inhibited by prion protein. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166209.	1.8	8
29	Dual effect of actin on the accessibility of myosin essential light chain A1 to papain cleavage. BBA - Proteins and Proteomics, 1998, 1383, 71-81.	2.1	6
30	PKA controls a level of topoisomerase I mRNA in mouse L5178Y lymphoma cells treated with db-cAMP. Molecular Biology Reports, 1994, 19, 93-97.	1.0	2
31	Mechanisms of the modulation of actin-myosin interactions by A1-type myosin light chains. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130132.	1.1	0